2023 was a tricky year for your biopharma industry, with several providers downsizing and restructuring their workforces to stay afloat. There are indications of recovery, as mergers and acquisitions picked up through the pharmaceutical and daily life sciences business in the latter part of 2023 and also have ongoing their https://sites.google.com/view/bio-sites/blog